inosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 3301 | 58-63-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D06BB05 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals |
| ATC | G01AX02 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Other antiinfectives and antiseptics |
| ATC | S01XA10 | SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.84 | acidic |
| pKa2 | 11.67 | acidic |
| pKa3 | 12.25 | acidic |
| pKa4 | 12.95 | acidic |
| pKa5 | 1.08 | Basic |
| pKa6 | 0.14 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000008090 | NUI |
| D00054 | KEGG_DRUG |
| C0021528 | UMLSCUI |
| CHEBI:17596 | CHEBI |
| NOS | PDB_CHEM_ID |
| CHEMBL1556 | ChEMBL_ID |
| DB04335 | DRUGBANK_ID |
| D007288 | MESH_DESCRIPTOR_UI |
| 135398641 | PUBCHEM_CID |
| 4554 | IUPHAR_LIGAND_ID |
| 4687 | INN_ID |
| 5A614L51CT | UNII |
| 1483575 | RXNORM |
| 003901 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rejuvesol | HUMAN PRESCRIPTION DRUG LABEL | 5 | 23731-7000 | SOLUTION | 1.34 g | EXTRACORPOREAL | NDA | 11 sections |
| Rejuvesol | HUMAN PRESCRIPTION DRUG LABEL | 5 | 23731-7000 | SOLUTION | 1.34 g | EXTRACORPOREAL | NDA | 11 sections |